Apixaban prophylactic anticoagulation in patients with nephrotic syndrome.

Background: Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic events (TE), due to hemostatic derangements. The use of direct oral anticoagulants (DOAC) in the prevention of TE hasn’t been studied intensively in patients suffering from NS. Methods: Retrospective analysis of consecutive incident patients with NS due to glomerular disease, receiving apixaban for thrombophylaxis. It is an uncontrolled, single center study. Results: We identified 27 patients treated with apixaban for the prevention of TE, in the context of NS. During follow-up apixaban Cmin and Cmax levels were measured. The mean duration of the anticoagulant treatment was 153 days (± 132). Patients were followed for a mean of 14.7 months (± 8.4) since the introduction of apixaban. Three patients had a TE at the time of NS diagnosis. Two patients had pulmonary embolism (PE) and one patient presented a stroke in lupus membranous nephropathy context. One patient developed PE approximately 2 months after introduction of apixaban treatment. No minor nor major bleeding events were noticed. Conclusion: The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had reduced risk of venous and arterial TE compared to patients previously described in the literature, without increased risk of bleeding.

Object Details

• Alternative title: Apixaban in nephrotic syndrome
• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Apixaban prophylactic anticoagulation in patients with nephrotic syndrome. ; day:08 ; month:08 ; year:2022 ; TH open ; (08.08.2022)

Contributors, Places and Time

• Contributor: VAN MEERHAEGHE, Tess ; Cez, Alexandre ; Dahan, Karine ; Esteve, Emmanuel ; Elalamy, Ismail ; Ponlot, Eleonore ; Boffa, Jean Jacques

Further information

• DOI: 10.1055/a-1920-6224
• URN: urn:nbn:de:101:1-2022092411235472348123
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:34 AM CEST